Who Is Ginkgo Bioworks and How Do They Fit in the Bio-Security, Transhumanist Agenda?

In May, biotech firm Ginkgo Bioworks announced it was going public with a valuation of $15 billion. Ginkgo is a rising star in the biotechnology field, describing themselves as “The Organism Company”. While their name is less known than other biotech giants such as Monsanto and Bayer, the scope of their research and projects will likely affect billions of people around the world in coming years.

Ginkgo Bioworks was founded in 2009 by a group of MIT scientists focused on “engineering biology” for a variety of purposes. Officially, Ginkgo Bioworks “designs, engineers, develops, tests and licenses organisms”. The company refers to their work as “biology by design”, stating that they “program cells to make everything from food to materials to therapeutics.” Ginkgo’s researchers use genetic engineering to design and “print” new DNA for a range of organisms, including plants and bacteria. These organisms can then be licensed out for artificial flavors and sweeteners, cosmetic ingredients, crop treatments and pharmaceuticals.